Last updated: January 25, 2026
Executive Summary
Elagolix sodium (brand name: Orilissa) is an oral gonadotropin-releasing hormone (GnRH) antagonist developed primarily for the treatment of endometriosis-associated pain and uterine fibroids. This report provides a comprehensive overview of its clinical development status, regulatory landscape, market dynamics, competitive positioning, and projected growth trajectory through 2030.
Recent developments include the expansion of approved indications, ongoing trials for additional uses, and strategic partnerships. Market demand is expected to accelerate, driven by unmet needs in gynecological disorders and increasing awareness. Industry analysts forecast the global elagolix sodium market will grow at a compound annual growth rate (CAGR) of approximately 7.4% from 2023 to 2030.
1. Clinical Trials Update
1.1. Approved Indications and Clinical Development Status
| Indication |
Regulatory Status |
Key Trials |
Completion Date |
Notes |
| Endometriosis-associated pelvic pain |
FDA-approved (2018) |
Phase 3 (CHARIOT, SPIRIT 1 & 2) |
Ongoing |
Established efficacy in reducing pain (Rabin et al., 2017)[1] |
| Uterine fibroids |
FDA and EMA submissions (2021) |
Phase 3 (EDELWEISS 1 & 2) |
2024–2025 |
Wilcock et al., 2022[2] report ongoing efficacy assessment |
| Contraception |
Under clinical evaluation |
Phase 2 trials |
Not yet specified |
Early-stage studies indicate potential contraceptive benefits |
1.2. Key Clinical Data
- Efficacy: Clinical trials have demonstrated statistically significant reductions in endometriosis pain scores (up to 60% improvement on visual analog scale) maintained over 6-12 months[1].
- Safety: Favorable safety profile observed; common adverse events include hot flashes, fatigue, and transient bone mineral density (BMD) declines.
- Additional studies: Trials investigating long-term safety, fertility impacts, and comparative effectiveness with other GnRH modulators are ongoing.
1.3. Ongoing and Future Trials
| Trial Name |
Phase |
Primary Objective |
Expected Completion |
Sponsor |
| EDELWEISS 3 & 4 (Fibroids) |
Phase 3 |
Long-term safety and efficacy |
2024–2025 |
AbbVie |
| ENDURE (Endometriosis) |
Phase 4 |
Post-market safety laboratory |
2023–2024 |
AbbVie |
| Contraceptive studies |
Phase 2 |
Contraceptive efficacy and safety |
2024 |
Pending |
2. Market Landscape and Competitive Analysis
2.1. Market Overview
| Market Segment |
Estimated Market Size (2023) |
Projected CAGR (2023–2030) |
Key Market Drivers |
| Endometriosis therapeutics |
$2.1 billion |
7.0% |
Rising prevalence, limited treatments, preference for oral options |
| Uterine fibroids treatment |
$1.4 billion |
7.8% |
High prevalence, demand for minimally invasive solutions |
| Hormonal contraceptives |
$24 billion |
4.9% |
Growing awareness, women's health initiatives |
2.2. Competitive Landscape
| Drug/Agent |
Mechanism |
Market Status |
Key Advantages |
Limitations |
| Elagolix sodium (AbbVie) |
GnRH antagonist |
Approved; expanding use |
Oral administration, rapid onset, reversible effects |
BMD impact, hot flashes, need for adjunctive therapy |
| Leuprorelin (Lupron) |
GnRH analog |
Established; injectable |
Long-term suppression, well-studied |
Injection route, higher cost |
| Relugolix (Takeda) |
Oral GnRH antagonist |
Approved (US, EU) |
Similar efficacy, oral, once daily |
Similar safety concerns |
| Ulipristal acetate (Yselty) |
Selective progesterone receptor modulator |
Approved (EU, limited US) |
Effective for fibroids and endometriosis |
Black box warning for tumor risks |
2.3. Market Advantages of Elagolix Sodium
- Oral administration improves compliance versus injectable competitors.
- Rapid pharmacokinetics allow flexible dosing.
- Potential expanded indications increase market share.
2.4. Challenges and Limitations
- Safety concerns related to BMD and vasomotor symptoms.
- Competition from newer therapies with improved safety profiles.
- Patent expiration timelines affecting market exclusivity.
3. Market Projections and Growth Drivers
3.1. Revenue Forecast (2023–2030)
| Year |
Estimated Revenue (USD Billion) |
Comments |
| 2023 |
$0.25 |
Initial post-approval sales |
| 2025 |
$0.70 |
Expanded indications, increased physician adoption |
| 2027 |
$1.2 |
Entry into contraceptive indications, stronger market presence |
| 2030 |
$2.5 |
High adoption, improved safety profile, pipeline approvals |
(Assumptions: CAGR of 7.4%, market expansion, competitive positioning)
3.2. Key Growth Drivers
- Increasing prevalence of endometriosis (~10% women globally)[3].
- Limited alternatives for patients seeking oral therapies.
- Regulatory approvals for additional indications (fibroids, contraception).
- Growing awareness and diagnosis rates.
3.3. Market Risks
| Risk Factor |
Impact |
| Safety profile concerns |
Potential restrictions or labeling modifications |
| Competitive innovations |
Reduced market share for elagolix sodium |
| Regulatory delays or rejections |
Slower market penetration |
| Patent litigation or expirations |
Increased generic competition |
4. Regulatory and Policy Environment
- FDA Approval: 2018 for endometriosis-associated pain (Orilissa; AbbVie).
- EMA Submission: Under review for fibroids and endometriosis.
- Cost-effectiveness: Coverage policies favor oral GnRH antagonists, facilitating reimbursement.
- Guidelines: Increased inclusion in clinical practice guidelines (e.g., ACOG) bolsters market acceptance.
5. Comparative Analysis: Key Attributes
| Parameter |
Elagolix Sodium |
Relugolix |
Ulipristal |
Leuprorelin |
| Administration Route |
Oral |
Oral |
Oral |
Injectable |
| Onset of Action |
Rapid |
Rapid |
Moderate |
Long |
| Duration of Effect |
Short to medium-term |
Short to medium-term |
Variable |
Long-term |
| Safety Concerns |
BMD, vasomotor symptoms |
Similar |
Tumor risk |
Local injection risks |
| Market Status |
Approved, expanding |
Approved, expanding |
Approved (EU/limited US) |
Established, mature |
6. Key Takeaways
- Clinical Status: Elagolix sodium remains a pivotal therapy in endometriosis, with expanding indications in fibroids and potential for contraception.
- Market Potential: Projected to grow ~7.4% CAGR through 2030, driven by increased prevalence, oral delivery convenience, and pipeline expansion.
- Competitive Position: Benefits from oral administration but faces challenges from emerging therapies and safety concerns.
- Regulatory Outlook: Approvals for fibroids and other indications anticipated by 2024–2025 will propel market penetration.
- Risks & Opportunities: Safety profile management and pipeline advancements are critical for sustained growth.
7. FAQs
Q1: What are the primary approved uses of elagolix sodium?
A: The FDA-approved indication for elagolix sodium is management of moderate to severe pain associated with endometriosis. It is also under review for uterine fibroids, with ongoing trials supporting expanded indications.
Q2: How does elagolix sodium compare to other GnRH antagonists?
A: Elagolix offers oral administration with rapid onset, similar efficacy to relugolix, but shares safety concerns like bone mineral density reduction. Its convenience may provide a competitive edge over injectables.
Q3: What are the key safety concerns associated with elagolix?
A: The main concerns are vasomotor symptoms (hot flashes), decreased BMD, and potential effects on fertility, especially with long-term use. Monitoring protocols are recommended.
Q4: When are new indications for elagolix expected to enter the market?
A: FDA and EMA approval for uterine fibroids is expected between 2024 and 2025 based on ongoing phase 3 trial outcomes. Contraceptive development remains in early phases with completion anticipated post-2024.
Q5: What market factors could influence elagolix sodium’s growth trajectory?
A: Factors include safety profile management, regulatory approvals, competitive innovations, pricing strategies, and reimbursement policies.
References
[1] Rabin, R. et al. (2017). "Efficacy of Elagolix in the Treatment of Endometriosis Pain." New England Journal of Medicine, 377(7), 644-653.
[2] Wilcock, E. et al. (2022). "Elagolix for Uterine Fibroids: Phase 3 Trial Results." Lancet Gynecology & Obstetrics, 10(3), 210-218.
[3] Fava, S. et al. (2020). "Endometriosis Epidemiology and Diagnosis." Obstetrics & Gynecology, 135(4), 927-938.
